Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

Detalles Bibliográficos
Autores principales: Kazda, Christof M., Ding, Ying, Kelly, Ronan P., Garhyan, Parag, Shi, Chunxue, Lim, Chay Ngee, Fu, Haoda, Watson, David E., Lewin, Andrew J., Landschulz, William H., Deeg, Mark A., Moller, David E., Hardy, Thomas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2017
Materias:
Errata
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439412/
https://www.ncbi.nlm.nih.gov/pubmed/28420698
http://dx.doi.org/10.2337/dc17-er06

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439412/
https://www.ncbi.nlm.nih.gov/pubmed/28420698
http://dx.doi.org/10.2337/dc17-er06

Ejemplares similares